The WorldHealth Organization (WHO) warns it still needs more data for that. The main vaccine permitted is the Bavarian Nordic, to prevent monkeypox and an important part of the global public health response.
“The European Medicines Agency (EMA) will discuss the possibility of a dose-efficient approach,” an EMA spokesperson said.
According to the US Food and Drug Administration, data collected in a 2015 clinical study show that dose savings can work without compromising vaccine safety and efficacy.
Meanwhile, several governments in Europe are taking other steps to extend existing supplies. For example, the UK offers only one injection of a two-dose regimen, to people most at risk as a temporary measure.
To provide some protection to more people. However, it is not clear whether both approaches will provide adequate protection against monkeypox.